Sonoma Biotherapeutics is Drug Discovery in United States that focus on developer business. Founded in 2019. They cover business area such as developer, autoimmune and degenerative disease, self-tolerance, harmful inflammatory response, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer, enable physician, critical disease.
2019
( 5 years old in 2024 )
Developer
-
400 East Jamie Circuit
Suite 20250
San Francisco, CA 94080
United States
Private
developerautoimmune and degenerative diseaseself-toleranceharmful inflammatory responseautoimmune diseaserheumatoid arthritisinflammatory bowel diseasemultiple sclerosisamyotrophic lateral sclerosisAlzheimerenable physiciancritical disease
* We use standard office opening hours in near Sonoma Biotherapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Sonoma Biotherapeutics is Drug Discovery business from United States that founded in 2019 (5 years old in 2024), Sonoma Biotherapeutics business is focusing on Developer.
Sonoma Biotherapeutics headquarter office and corporate office address is located in 400 East Jamie Circuit Suite 20250 San Francisco, CA 94080 United States.
Sonoma Biotherapeutics was founded in United States.
In 2024, Sonoma Biotherapeutics is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Sonoma Biotherapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
